| |||||||||||||||||||
![]() ![]() ![]() ![]() ![]() ![]() ![]()
|
![]()
April 24, 2000 Dockets Management Branch (HFA-305) Re: Market Exclusivity and Patent Dear Sir or Madam: The Pharmaceutical Research and Manufacturers of America ("PhRMA")
submits these comments on the proposed rule published by the Food and
Drug Administration ("FDA") on January 24, 2000, concerning marketing
exclusivity and patent provisions for antibiotic drugs under the Food
and Drug Administration Modernization Act of 1997 ("FDAMA"). PhRMA is a voluntary, non-profit association that represents the
country's leading research-based pharmaceutical and biotechnology
companies. These companies are devoted to research on medicines that
allow patients to lead longer, healthier, and more productive lives.
PhRMA member companies invest approximately $24 billion annually to
discover and develop new medicines. These companies are the source of
nearly all new drugs — including antibiotic drugs — that are discovered
and evaluated throughout the world. PhRMA believes FDA's Proposed Rule is inconsistent with any rational
interpretation of the relevant provisions of FDAMA and contradicts the
intent of Congress to promote innovation in the field of antibiotic
drugs. Accordingly, PhRMA requests FDA to revise its Proposed Rule. I.FDA'S PROPOSED RULE IS INCONSISTENT WITH ANY RATIONAL
INTERPRETATION OF THE FDAMA PROVISIONS. Section 125(b) of FDAMA repealed Section 507 of the Federal Food,
Drug, and Cosmetic Act ("FD&C Act") (21 U.S.C. 357 (1996)). Section
507 was the section of the FD&C Act under which the agency certified
antibiotic drugs. Section 125(d)(1) of FDAMA provides that marketing applications for
antibiotic drugs that were approved under former Section 507 of the
FD&C Act will be considered to have been submitted and approved
under the new drug application ("NDA") submission and approval
provisions found at Section 505(b) and (c) of the FD&C Act (21
U.S.C. 355(b) and (c)). If the marketing application was an approved
abbreviated antibiotic drug application, it will be considered to have
been submitted and approved under the abbreviated new drug application
("ANDA") provisions found in Section 505(j) of the FD&C Act. FDAMA also exempts certain antibiotic-related drug marketing
applications from the marketing exclusivity and patent provisions found
in Section 505 of the FD&C Act.[1]
Under former Section 507 of the FD&C Act, antibiotic drug
applications were not subject to the patent listing and exclusivity
provisions in Section 505 of the FD&C Act. Section 125 of FDAMA preserves this distinction by providing that
"[d]rugs that were approved and marketed under former Section 507 of the
FD&C Act, as well as those that were the subject of applications
that may have been withdrawn, not filed, or refused approval under
Section 507 of the FD&C Act are excluded from the patent listing and
exclusivity provisions." 65 Fed. Reg. at 3624. Specifically, FDAMA provides that: [t]he following subsections of Section 505 (21 U.S.C. 355)
Pub. L. No. 105-115, 111 Stat. 2295, 2326-2327 (1997) (emphasis
added). A.FDA Erroneously Focuses On The Definition Of "Antibiotic"
To Support The Rationale Of Its Proposed Rule. In the Proposed Rule, FDA has erroneously concluded that the
determination under Section 125(d) of FDAMA of whether a drug contains a
pre-repeal antibiotic depends on whether the drug that is the subject of
a marketing application contains an active moiety that can be found in a
pre-repeal antibiotic drug. 65 Fed. Reg. at 3625. FDA's conclusion is
inconsistent with any rational interpretation of FDAMA. FDA's error begins with its focus on the term "any derivative" in the
definition of antibiotic drug that appeared in former Section 507 of the
FD&C Act and was repeated in Section 125(d) of FDAMA. The term
"antibiotic drug," as used in Section 125(d) of FDAMA, is defined
as: ". . . any drug (except drugs for use in animals other than
humans) FDA first asserts that "any derivative" means derivatives such as
salts or esters of a substance. By limiting "any derivative" to salts or
esters, FDA then uses this language to support its rationale for the use
of "active moiety" as the standard for the determination of pre-repeal
antibiotics. FDA's regulations define an active moiety as "the molecule
or ion responsible for physiological or pharmacological action,
excluding appended portions that would cause the drug to be an ester,
salt, or other noncovalent derivative of the molecule." 21 C.F.R.
314.108(a). The problem, however, is that the "active moiety" definition is
limited to "non-covalent" derivatives of the molecule. FDA
does not and cannot provide an explanation for arbitrarily excluding
covalent derivatives from its determination of pre-repeal antibiotic
drugs that is based on the term "any derivative."
Although, under FDA's incorrect interpretation, the FDAMA language would
require the exclusion of covalent derivatives from the benefits of the
Hatch-Waxman Act, the exclusion of such derivatives from patent listings
and market exclusivity would eviscerate all incentives for the great
majority of antibiotic innovations that are likely to occur in the
foreseeable future. FDA's erroneous focus on the term "any derivative"
to support its rationale makes this result both statutorily required and
logically absurd. B.FDA's Proposed Rule Would Provide Fewer Incentives For
Antibiotic Innovation Than Are Provided For Innovation In Other
Drug Categories. According to the Proposed Rule, "FDA has consistently looked at
active moieties to determine whether the exclusivity protection granted
to a drug product would allow a subsequent ANDA or application described
in Section 505(b) of the FD&C Act to be submitted or approved." 65
Fed. Reg. at 3625. Although this statement accurately reflects FDA's
practices with respect to approvals of ANDAs and applications described
in 505(b)(2) of the FD&C Act, FDA is erroneously applying the same
standard in the context of the antibiotic provisions of FDAMA.
Application of the same standard in this context produces markedly
different consequences. In the Hatch-Waxman context, the term "active moiety" is used
exclusively for a determination of whether the NDA product receives five
years of data exclusivity as a new chemical entity ("NCE") or three
years of data exclusivity as a non-NCE. The concept of "active moiety"
is not used to determine whether patents can be listed for the
modification to the original drug. Similarly, the concept of active
moeity is not used to prevent three-year exclusivity if the subsequent
NDA or NDA supplement for the modification otherwise meets the criteria
for non-NCE data exclusivity. In contrast, under FDA's interpretation of the antibiotic rule, the
concept of "active moiety" will both prevent patent listings for the new
NDA or NDA supplement, and it will prevent non-NCE data exclusivity,
even when clinical studies are required to support approval of the
modification. As the Proposed Rule states: NDA's for products that contain, for example, a salt of a
pre-repeal antibiotic drug, or that propose such things as a new
manufacturing process, new dosage form, or new use of a pre-repeal
antibiotic drug, will be subject to the exceptions listed in Section
125(d)(2) of [FDAMA] and proposed § 314.109(a).
65 Fed. Reg. at 3625. According to FDA's Proposed Rule, these changes
would neither be eligible for patent listings nor eligible for non-NCE
data exclusivity. However, under the operation of the Hatch-Waxman Act
for other drugs, each of these changes would be eligible for patent
listings for relevant patents and data exclusivity if they rely on new
studies. Therefore, FDA's approach creates fewer incentives for
innovation for antibiotics than exist for other drugs. Congress intended the repeal of Section 507 of the FD&C Act to
place antibiotic drugs that are the subject of post-repeal marketing
applications in a position to have the same incentives for innovation as
other drugs. FDA's Proposed Rule, however, will place post-repeal
antibiotics in a less favorable position than other drugs. This was not
the intent of Congress, and FDA cannot assert that it was. II.A "DRUG" THAT WAS THE SUBJECT OF A PRE-REPEAL
APPLICATION MUST BE INTERPRETED TO MEAN "DRUG PRODUCT" The definition of antibiotic drug in Section 125(d) of FDAMA[2]
merely defines the types of drugs that are "antibiotic." As described
above, it does not and cannot define the scope of products that are
excluded from the benefits of the Hatch-Waxman data exclusivity and
patent listing requirements. The FD&C Act defines "drug" broadly to cover both a finished drug
product and its active ingredient or ingredients and delegates to FDA
the task of determining how to apply that definition in particular
instances. Any interpretation of the relevant language in the FDAMA
exclusion for pre-repeal antibiotic drugs must focus on the word
"drug." A."Drug Product" Is The Only Meaning Of Drug That Avoids An
Absurd Result. "Drug product" means a finished dosage form, e.g., tablet,
capsule, or solution, that contains the active drug ingredient,
generally, but not necessarily, in association with inactive
ingredients. 21 C.F.R. &$167; 320.1(b). "Drug substance" means an
active ingredient that is intended to furnish pharmacological activity
or other direct effect in the diagnosis, cure, mitigation, treatment, or
prevention of disease or to affect the structure or any function of the
human body, but does not include intermediates used in the synthesis of
such ingredient. Id. In this regard, the ester form is a
different active ingredient from the salt form. Accordingly, "Drug
Product" is the only meaning of drug that will provide post-repeal
antibiotic products with the same incentives for innovation under the
Hatch-Waxman Act as other drug products.[3]
Indeed, in a nearly identical statutory construction, FDA interpreted
the word drug to mean "drug product." Pfizer, Inc. v. Food and
Drug Administration, 753 F. Supp. at 171, 174 (D. Md. 1989)
(magistrate's report and recommendation), adopted 753 F. Supp. at 176.
The Pfizer court adopted the magistrate's recommendation that, in
the context of Section 505 of the FD&C Act, "FDA's interpretation of
drug as meaning drug product is consistent with and indeed required by
the statute."[4]
Section 505(b)(1) and (c)(2) of the FD&C Act refers to a "drug
for which the applicant submitted the application." 21 U.S.C. §§ 355
(b)(1) and (c)(2). This statutory language is substantively the same as
"a drug that is the subject of the application" that is described in
Section 125(d) of FDAMA. The interpretation of "drug" as "drug product"
is equally compelled in the language of Section 125(d) of FDAMA. B."Drug Product" Is The Only Meaning Of Drug That Complies
With The Legislative History. Section 125(d) of FDAMA states that the product is not eligible for
exclusivity if "the antibiotic drug was the subject of the subject
of any application for marketing received . . . before the date
of the enactment of [FDAMA]."[5]
The legislative history shows that this provision is
application-specific. It also follows that "drug product" is the only
meaning of "drug" that will achieve the application-specific intent of
the legislative history. The House of Representatives Report states that: "[t]he repeal of Section 507 [of the FD&C Act] also results
in applications for new antibiotic products being submitted to the
FDA under all the requirements and benefits of Section 505,
including the granting of market exclusivity to all new drugs under
the so-called Waxman-Hatch provisions."[6] The House Report confirms that the FDAMA provision is
application-specific: "The repeal of Section 507 [of the FD&C Act]
also results in applications . . . being submitted under
all the requirements and benefits of Section 505, . . ." The 505
benefits accrue to applications, and applications refer to drug
products. Similarly, the House Report discusses "applications for new
antibiotic [drug] products;" it does not discuss
applications for new antibiotic active moeities. Moreover, in May 1998, only a few months after the enactment of FDAMA
in November 1997, the principal drafters of FDAMA expressly confirmed
that the exclusion from the benefits of the Hatch-Waxman Act were
application-specific.[7]
According to the drafters of the provision, Congress provided that the Hatch-Waxman exclusion applied to: any application for marketing in which the
drug that is the subject of the application
contains an antibiotic drug was the subject of any
application received [by FDA] . . . before the
date of enactment of [FDAMA]. This unambiguous transition provision
is application-oriented. By its own term, it covers
applications for "Antibiotic drug[s]." It plainly does not cover new
molecular entities that are indirectly or directly related to the
antibiotic drug that is the subject of an excluded application for
an "old antibiotic."[8] Thus, the exclusion from Hatch-Waxman benefits is
application-specific, and the term antibiotic "drug" must mean
antibiotic "drug product" to achieve the application-specific intent of
Congress. III.CONCLUSION For the reasons described above, PhRMA urges FDA to withdraw its
erroneous interpretation of Section 125(d) of FDAMA. Instead, FDA must
interpret Section 125 to provide the benefits of the Hatch-Waxman to
post-repeal antibiotics to the same extent as those benefits are
available to other drugs under Section 505 of the FD&C Act. This
approach is both consistent with the statutory language and furthers the
congressional intent of encouraging innovation in antibiotic drug
products. Sincerely yours, Matthew B. Van Hook [1]
The FDAMA does not affect whatever rights patent holders may have
regarding patent term extensions under 36 U.S.C. 156 for patents
claiming antibiotic drug products. [2]
The term "antibiotic drug," as used in
Section 125(d) of the Modernization Act, is defined as: Ò. . . any drug (except drugs for use in
animals other than humans) composed wholly or partly of any kind of
penicillin, streptomycin, chlorictracycline, chloramphenicol,
bacitracin, or any other drug intended for human use containing any
quantity of any chemical substance which is produced by a micro-organism
and which has the capacity to inhibit or destroy micro-organisms in
dilute solution (including a chemically synthesized equivalent of any
such substance) or any derivative thereof. 21 U.S.C. 321(jj). [3]
The "drug substance" definition would still preclude modifications such
as new manufacturing process, new dosage form and new uses of a
pre-repeal antibiotic drug from patent listings in all cases and from
non-NCE data exclusivity in the circumstances when these modifications
rely on new clinical studies for approval. [4]
Id. at 176, (district court referring to and adopting the
recommendation of the magistrate). [5]
Section 125(d) of FDAMA (emphasis added). [6]
H.R. Rep. No. 105-310 (1997) (emphasis added). [7]
Letter from Rep. Tom Bliley, Chairman, House Commerce Committee, Rep.
Michael Bilirakis, Chairman, House Commerce Subcommittee on Health and
Environment, and Richard Burr, member of the House Commerce Committee to
Michael A. Friedman, M.D., Lead Deputy Commissioner, United States Food
and Drug Administration (May 21, 1998), reprinted in FDA WEEK,
January 28, 2000. [8]
Id. at 1-2. | ||||||||||||||||||
![]() |
Privacy
Policy • Members
Site • Contact
Us • Site
Credits • Site Map • Employment
Pharmaceutical Research and Manufacturers of America |
![]() At the State Level Issues Around the World New Drugs in Development Prescription Drug Costs Seniors and Prescription Drugs Other Issues PhRMA Foundation News |